Denali Therapeutics Inc (DNLI) Return on Investment ROI from the third quarter of 2026 to third quarter of 2025 and for the year 2026, average high and low, overall ranking from Sep 30 2026 to Sep 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Denali Therapeutics Inc   (NASDAQ: DNLI)


Denali Therapeutics Inc's ROI from its third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Denali Therapeutics Inc's ROI in the third quarter of 2026?
Denali Therapeutics Inc achieved a return on average invested assets (ROI) of 17.88 % in its third quarter of 2026, this is above DNLI's average return on investment of -7%.
Denali Therapeutics Inc invested over the 12 months ending in its third quarter of 2026 $1,108 million

ROI has improved compared to 0.09% in the second quarter of 2026, due to net income growth.

Within the Healthcare sector 186 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the second quarter of 2026 from 1584 to 2451.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Sep 30 2026)
III. Quarter		 (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter
Y / Y Investment Change TTM -1.36 % -13.44 % -19.12 % -23.34 % -16.53 %
Y / Y Net Income Change TTM - - -93.48 % - -
Investment (TTM) in Millions 1,161 1,068 1,156 1,047 965
Return On Investment (TTM) 17.88 % 0.09 % 0.42 % -0.01 % -6.77 %
DNLI's Overall Ranking # 2451 # 1584 # 1805 # 2775 #
Seq. Investment Change TTM 4.61 % -0.17 % -0.55 % -5.02 % -8.2 %
Seq. Net Income Change TTM 19962.31 % -77.67 % - - -
Net Income (TTM) in Millions 198 1 4 0 -76

DNLI Company Profile >> Back to DNLI Roi Comparisons >> See Annual DNLI Return On Investment



Return On Investment DNLI's Ranking
Within: No.
Industry # 19
Sector # 187
Overall # 2451

Return On Investment Statistics
High Average Low
30.56 %
-7 %
-37.66 %
(Jun 30 2023)   (Dec 31 2021)



  News about Denali Therapeutics Inc Return on Investment ROI

Denali Therapeutics Charts Ambitious Course for 2025 Amid Financial Challenges and Pivotal FDA Discussions on Hunter Syndrome Therapy,

January 13, 2025

Denali Therapeutics Sets Ambitious 2025 Milestones Despite Financial StrugglesDenali Therapeutics Inc. a biotech firm focused on developing therapies for neurodegeneration and lysosomal storage diseases, recently outlined its key anticipated milestones for 2025. The company’s Chief Executive Officer, Ryan Watts, Ph.D. is scheduled to present these goals at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025. This presentation comes amid the backdrop of significant financial challenges, as Denali has reported a cumulative net loss of $366 million for the 12 months ending in the third quarter of 2024. This translates to a concerning negative return on investment (ROI) of -27.29%. In terms of financial performance, Denali s position is not favorable compared to its peers within the healthcare sector, as 337 other companies boasted a higher ROI during the same period. However, there is a slight improvement observe in Denali s overall ranking, with its ROI increasing from 3476 in the second quarter of 2024 to 3018 by September 30, 2024. This indicates a progressing position, albeit off a low base.One of the key highlights for Denali Therapeutics is its recent engagement with the U.S. Food and Drug Administration (FDA) regarding Tividenofusp Alfa (DNL310), the company’s investigational treatment for Mucopolysaccharidosis Type II (MPS II), alternatively known as Hunter Syndrome. This meeting was instrumental in paving the way for the company to seek accelerated approval from the FDA. This pathway is particularly valuable as it may expedite patient access to treatments that address significant unmet medical needs.





Financial Statements
Denali Therapeutics Inc's III. Quarter Investments $ 1,161 Millions DNLI's Balance sheet
Denali Therapeutics Inc's III. Quarter Income $ 70 Millions Quarterly DNLI's Income Statement
DNLI's Income by Division See DNLI's Income by Division


DNLI Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 1,047 1,272 1,076 1,096 1,026
Y / Y Investment Growth -17.73 % 18.22 % -1.86 % 6.86 % -33.06 %
Net Income in Millions 0 0 0 0 1
Y / Y Net Income Growth - - - - -99.6 %
Annual Return On Investment -0.01 % -0.01 % -0 % -0 % 0.06 %


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Biotechnology & Pharmaceuticals Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
DNLI's Roi Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for DNLI's Competitors
Subscribers only: Roi for Denali Therapeutics Inc's Suppliers
Subscribers only: Return On Investment for DNLI's Customers

Other Ratios
DNLI's Roa DNLI's Inventory Turnover Ratio DNLI's Growth Rates DNLI's Dividend Statistics
DNLI's Profitability Ratios DNLI's Asset Turnover Ratio DNLI's Dividend Growth
DNLI's Roe DNLI's Valuation Ratios DNLI's Financial Strength Ratios DNLI's Dividend Payout Ratio



Companies with similar Return On Investment at Sep 30 2026, within Healthcare Sector ROI
Oramed Pharmaceuticals Inc  48.08 %
Aurinia Pharmaceuticals Inc   45.04 %
Nurix Therapeutics Inc   44.12 %
Medpace Holdings Inc   41.14 %
Rallybio Corporation  36.04 %
Eli Lilly And Company  32.00 %
Caredx Inc   30.65 %
Zevra Therapeutics Inc   29.88 %
Qhslab Inc   27.35 %
Acadia Pharmaceuticals Inc   26.89 %
Protalix Biotherapeutics inc   26.06 %
Standard Biotools Inc   23.91 %
Electromed Inc   23.41 %
Iradimed Corporation  22.98 %
Corcept Therapeutics Inc  22.08 %
Resmed Inc   21.10 %
Alector Inc   20.83 %
Chemed Corporation  20.46 %
Halozyme Therapeutics Inc   19.64 %
Pro dex Inc   19.11 %
Dexcom Inc   18.92 %
Illumina Inc   18.74 %
Denali Therapeutics Inc   17.88 %
West Pharmaceutical Services Inc   17.65 %
Healthcare Services Group Inc   17.18 %
Neurocrine Biosciences Inc   16.94 %
Krystal Biotech Inc   16.91 %
Vertex Pharmaceuticals Inc  16.63 %
Sanuwave Health Inc   16.50 %
Intuitive Surgical Inc   16.30 %

Date modified: 2026-11-04T16:54:19+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.